A Director at Myriad Genetics (NASDAQ: MYGN) is Buying Shares

By Carrie Williams

Today, a Director at Myriad Genetics (MYGNResearch Report), John Henderson, bought shares of MYGN for $164.2K.

Following this transaction John Henderson’s holding in the company was increased by 2333.33% to a total of $1.54 million.

See today’s analyst top recommended stocks >>

Based on Myriad Genetics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $215 million and GAAP net loss of $4.2 million. In comparison, last year the company earned revenue of $202 million and had a GAAP net loss of $700K. The company has a one-year high of $48.40 and a one-year low of $20.10.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life.